Immune Modulators in Women Undergoing IVF----a Prospective Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- In Vitro Fertilization
- Sponsor
- Weill Medical College of Cornell University
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- To explore the relationship between immune mediators and IVF outcome prospectively in women who receive in vitro fertilization treatment.
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
Exploring the immune mediators of early pregnancy prospectively may help to identify new early interventions that will increase the likelihood of success and help women make informed decisions regarding their pregnancies.
Detailed Description
Sera will be obtained from 500 women undergoing IVF at five time periods: cycle Day 2, post HCG, Day 24, Day 28, and/or Day 35.Aliquots of sera will be tested by commercial ELISA kits for concentrations of immune modulators suggestive to be predictive of IVF outcome, such as cytokines (interleukins, tumor necrosis factor, and interferon), neurotrophins (BDNF), protease inhibitors (HE4) and insulin-like growth factors (IGF-1, IGF-2, IGFBP). The results will be correlated with IVF outcomes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All fresh transfers
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
To explore the relationship between immune mediators and IVF outcome prospectively in women who receive in vitro fertilization treatment.
Time Frame: 35 days